Trials / Completed
CompletedNCT06432764
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn's Disease.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the changes in intestinal uptake of radioligand \[11C\]AZ14132516 following multiple doses of AZD7798 in participants with Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD7798 | Each participating patient will receive the study drug as specified in the study protocol. |
| DRUG | [11C]AZ14132516 | A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination |
Timeline
- Start date
- 2024-10-16
- Primary completion
- 2026-03-27
- Completion
- 2026-03-27
- First posted
- 2024-05-29
- Last updated
- 2026-04-14
Locations
1 site across 1 country: Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06432764. Inclusion in this directory is not an endorsement.